Medicare Part B spending for Bristol-Myers Squibb Company’s Orencia and UCB S.A.’s Cimzia during 2017 and 2018 was nearly $500m higher than it should have been because of the way average sales prices for the two drugs was calculated, the Health and Human Services Department Office of Inspector General concluded in a report released 8 July.
The report focuses on the Centers for Medicare and Medicaid Services practice of including the higher prices of self-administered...







